Characterization of the EM66 Biomarker in the Pituitary and Plasma of Healthy Subjects With Different Gonadotroph Status and Patients With Gonadotroph Tumor
Open Access
- 22 February 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 102
Abstract
Granins and their derived-peptides are useful markers of secretion from normal and tumoral neuroendocrine cells. The need to identify new diagnostic markers for neuroendocrine tumors, including pituitary tumors prompted us to determine plasma levels of the secretogranin II-derived peptide EM66 in healthy volunteers with different gonadotroph status and to evaluate its usefulness as a circulating marker for the diagnosis of gonadotroph tumor. Using a radioimmunoassay, we determined plasma EM66 concentrations in healthy men and women volunteers in different physiological conditions in relation with the gonadotroph function. Our results revealed that in men, in women with or without contraception, in pregnant or post-menopausal women, plasma EM66 concentrations are not significantly different, and did not show any correlation with gonadotropin levels. In addition, stimulation or inhibition tests of the gonadotroph axis had no effect on EM66 levels, whatever the group of healthy volunteers investigated while gonadotropin levels showed the expected variations. Immunohistochemical experiments and HPLC analysis showed the occurrence of EM66 in pituitary gonadotroph, lactotroph and corticotroph tumors but not in somatotroph tumor. In patients with gonadotroph or lactotroph tumor, plasma EM66 levels were 1.48 (0.82–4.38) ng/ml and 2.49 (1.19–3.54) ng/ml, respectively. While median value of EM66 was significantly lower in patients with gonadotroph tumor compared to healthy volunteers [2.59 (0.62–4.95) ng/ml], plasma EM66 concentrations were in the same range as normal values and did not show any correlation with gonadotropin levels. These results show that plasma EM66 levels are independent of the activity of the gonadotroph axis in healthy volunteers and, while EM66 levels are reduced in gonadotroph tumors, plasma EM66 does not provide a helpful marker for the diagnosis of these tumors.Keywords
This publication has 47 references indexed in Scilit:
- Secretoneurin stimulates the production and release of luteinizing hormone in mouse LβT2 gonadotropin cellsAmerican Journal of Physiology-Endocrinology and Metabolism, 2011
- Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptorsEndocrine-Related Cancer, 2009
- Impact level of dihydrotestosterone on the hypothalamic‐pituitary‐leydig cell axis in menInternational Journal of Andrology, 2009
- Expression and Processing of the Neuroendocrine Protein Secretogranin II in Benign and Malignant PheochromocytomasAnnals of the New York Academy of Sciences, 2006
- PACAP Stimulates the Release of the Secretogranin II-Derived Peptide EM66 from Chromaffin CellsAnnals of the New York Academy of Sciences, 2006
- Biochemical Characterisation and Immunohistochemical Localisation of the Secretogranin II‐Derived Peptide EM66 in the Hypothalamus of the Jerboa (Jaculus orientalis): Modulation by Food DeprivationJournal of Neuroendocrinology, 2005
- Direct estradiol down-regulation of secretogranin II and chromogranin A mRNA levels in rat pituitary cellsMolecular and Cellular Endocrinology, 1992
- The gonadotrope polypeptide (GP 87) released from pituitary cells under luteinizing hormone—releasing hormone stimulation is a secretogranin II formBiochimie, 1988
- Human pituitary gonadotropic adenoma; histological, immunocytochemical, and ultrastructural and hormonal studies in eight casesThe Journal of Pathology, 1981
- Purification of rat prolactin : Development of an homologous radioimmunological assay and comparison with the NIAMDD systemAnnales de Biologie Animale Biochimie Biophysique, 1979